0 Evaluaciones
ID

32982

Descripción

Study ID: 104020 Clinical Study ID: 104020 Study Title: Blinded, randomised study to assess the immunogenicity and safety of GlaxoSmithKline (GSK) Biologicals’ live attenuated measles-mumps-rubella-varicella candidate vaccine when given to healthy children in their second year of life Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00126997 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 4 Study Recruitment Status: Completed Generic Name: Combined Measles, Mumps, Rubella, Varicella Vaccine Trade Name: Priorix Tetra Study Indication: Measles; Mumps; Rubella; Varicella

Palabras clave

Versiones (1)
  1. 22/11/18 22/11/18 -
Titular de derechos de autor

GSK group of companies

Subido en

22 de noviembre de 2018

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY-NC 3.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

  • El más nuevo
  • Más antiguo
  • Popular
  • El más nuevo
    • El más nuevo
    • Más antiguo
    • Popular

    Sin comentarios

    Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

    Immunogenicity of Combined Measles, Mumps, Rubella, Varicella Vaccine for healthy 2 y.o children - 104020

    Inglés

    Elimination Criteria

    1 formularios  
    1. StudyEvent: ODM
      1. Elimination Criteria
    Note
    Descripción

    Note

    Check the following criteria at each visit. If any criteria become applicable during the study, it will not require withdrawal of the subject from the study but may determine a subject's evaluability in the according-to-protocol (ATP) analysis
    Descripción

    Check the following criteria at each visit. If any criteria become applicable during the study, it will not require withdrawal of the subject from the study but may determine a subject's evaluability in the according-to-protocol (ATP) analysis

    Tipo de datos

    text

    Elimination Criteria
    Descripción

    Elimination Criteria

    Check all that apply
    Descripción

    Check all that apply

    Tipo de datos

    text

    Volver a la parte superior de la página

    Similar models

    Elimination Criteria

    1 formularios
    1. StudyEvent: ODM
      1. Elimination Criteria
    Name
    Tipo
    Description | Question | Decode (Coded Value)
    Tipo de datos
    Alias
    Item Group
    Note
    Check the following criteria at each visit. If any criteria become applicable during the study, it will not require withdrawal of the subject from the study but may determine a subject's evaluability in the according-to-protocol (ATP) analysis
    Item
    Check the following criteria at each visit. If any criteria become applicable during the study, it will not require withdrawal of the subject from the study but may determine a subject's evaluability in the according-to-protocol (ATP) analysis
    text
    Item Group
    Elimination Criteria
    Item
    Check all that apply
    text
    Check all that apply
    Code List
    Check all that apply
    CL Item
    Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) during the study period. (1)
    CL Item
    Newly diagnosed immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection, during the study period (2)
    CL Item
    Administration of a licensed vaaccine not foreseen in the study protocol during the study (30 days prior to the first vaccicnation until study end(Week 12)). (3)
    CL Item
    Chronic administration (defined as more than 14 days) of immunosuppresants or other immunemodifying drugs during the study period. (For corticosteroids, this will mean prednisone, or equivalent, >= 0.5 mg/kg/day. Inhaled and topical steroids are allowed.) (4)
    CL Item
    Administration of immunoglobulins and/or any blood products during the study period. (5)
    Volver a la parte superior de la página 

    Ayuda

    Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

    Watch Tutorial